LA Pharma produce every oral and injectable steroids which is mostly used for bodybuilding steroid cycles and what is most important they have affordable prices for TOP quality products. Drug testing services can be an effective harm reduction service that may strengthen surveillance of the black-market drugs that are used and can accurately inform users about the quality and quantity of black market AAS prior to use . Effective harm reduction strategies, evidence-based guidelines and interventions are urgently needed to protect users from counterfeit products found on the black market, and to support the development of effective services. The most common route of administration is per intramuscular injection and we demonstrate that proportions of counterfeit and substandard substances for injectables compared to oral formulations may be considerably higher. The very wide range in the proportions of counterfeit or substandard AAS from the black market shows the uncertainty about quality, thus leaving users with unpredictable risks. Rather than caused by study design issues, the differing proportions of counterfeit or substandard AAS reflect the selection of the tested AAS samples, with real differences in the quality of AAS found on the black market. With this systematic review and meta-analysis, we demonstrate that substantial mean proportions of black-market AAS are counterfeit and of substandard quality. The very wide range in proportions of counterfeit or substandard black market AAS puts the user in a situation of unpredictable uncertainty. ‘Drug checking’ allows people who consume illegal and legal drugs acquired from unregulated drug markets to submit samples for chemical analysis and receive feedback on the quantity, quality, and purity of those substances. Importantly, there are more than 60 different anabolic androgenic steroids listed on the WADA prohibited list and novel compounds are frequently detected on the market. There is a broad availability of different analytical tools used to identify counterfeit AAS on the black market, as included in this systematic review. Although these proportions must be interpreted with caution due to some methodological challenges and high heterogeneity, one must acknowledge the unreliable nature of those substances acquired from the black market. In 18 articles, counterfeit substances and only in eight articles, substandard substances were presented. Some articles also included other classes of substances in their analysis, such as WADA classes S2, S3, S4, S5, dietary supplements, stimulants, and sexual performance enhancers. While metandienone is controlled and no longer medically available in the U.S., it continues to be produced and used medically in some other countries. Generic production shut down two years later, when the FDA revoked metandienone's approval entirely in 1985. Following further FDA pressure, CIBA withdrew Dianabol from the U.S. market in 1983. Counterfeit proportions for oil-based solutions compared to tablets are described as 43–65% vs. 29–37%, respectively 25, 43. Some authors have analyzed and compared the quantity and quality of different AAS formulations. If smaller, statistically not significant studies tend to remain unpublished, then an asymmetrical shape may be observed. For "over-concentrated" preparations however, active ingredients could go as much as 200% above that indicated on the label (e.g. 221% or 225% ) if quantitative data was available. For most original substances, we were able to extract qualitatively analyzed data (accurately labeled) and only for 37% were we able to extract qualitatively and quantitatively analyzed data (accurately labeled and concentration within range as declared on the label). In seven articles (37%), both main endpoints were presented simultaneously. Analytical methods can vary considerably in terms of instrumentation cost, analysis time, and identification and quantification software. We demonstrate that visual inspection of the package, label, and internal content to identify preliminary signs of counterfeiting of AAS have shown to be mostly ineffective. Interestingly, this systematic review showed significant differences between the two included world regions. AAS were the most dominant group within all analyzed products, and they were almost exclusively analyzed within the WADA class S1. Some authors assessed visual inspection of packaging and detection of counterfeiting rate with contradicting results. We demonstrate that on some occasions completely different pharmaceuticals were identified during the analysis, such as quinine (antimalarial drug), instead of AAS. We provide evidence that AAS are more likely to be under-concentrated than over-concentrated if they are of substandard quality. In the case of mislabeled AAS acquired on the black market, it is currently not exactly known what is consumed by the user. Unknowingly taking the wrong formulation can lead to unexpected side effects, especially when taken over a longer period than intended or in combination with other substances. Among the included studies, most approaches are based on liquid chromatography coupled to mass spectrometry (LC–MS/MS) 32, 42, 47, 49, 50, or gas chromatography coupled to mass spectrometry (GC–MS) 32, candy96.fun 35, 40, 42, 47, 49, 51–54. Funnel plot for counterfeit AAS (left), funnel plot for substandard AAS (right). In some studies, the contained active ingredients in "under-concentrated" preparations was much lower than 50% of that indicated (e.g. 0.5–1.5% , 9% or 16% ) if quantitative data was available. Firstly, defined ranges of declared labels could vary massively between articles, had a quantitative analysis been performed, with defined ranges between 50–200% , 80–130% , 80–120% or 90–110% . Importantly, whenever anabolic agents were analyzed with other classes of substances, anabolic agents made the highest proportion of analyzed classes. In 17 articles we were able to extract samples that exclusively analyzed anabolic agents (WADA class S1). Research in the Americas was only done in Brazil, which alone includes 7 of the 19 studies. The authors provided sufficient information in the methods section so that, by consensus between the reviewers (RM/PB/LF), we were confident to include the study for extraction and analysis. For one study, the study design (retrospective database analysis) did not qualify for the analysis by ToxRtool and was individually assessed by the study team . All quality appraisal results can be found in Supplementary file 1. Additional articles were excluded after full-text assessment for the reasons mentioned in the flowchart (Fig. 1). We retrieved a total of 24 full-text articles from these different sources. We conducted a systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 (PRISMA) statement . To our knowledge, this is the first systematic literature review analyzing fake black-market AAS within the published literature. Counterfeit products can potentially lead to negative health outcomes and are considered an individual and public health threat . Injectable testosterone, synthetic AAS, other hormones and adjunctive therapies can easily be purchased over the internet and are delivered to a consumer’s home without prescription 4, 6, 8. Due to lack of reporting, precise prevalence and demographic information on the use of these substances is challenging . AAS belong to the broader group of image and performance enhancing drugs (IPEDs) and are widely used as a convenient and easy method to improve body image and sport performance goals .